Health Canada approves Levemir® FlexTouch® prefilled insulin pen for the treatment of type 1 and type 2 diabetes MISSISSAUGA, ON, Oct. 18, 2013 /CNW/ - Novo Nordisk today announced that ...

The U.S. Food and Drug Administration has approved Novo Nordisk's prefilled insulin pens called the NovoLog® FlexTouch® and Levemir® FlexTouch®.

The Danish drugmaker said supply disruptions would start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Novo has another ...

Susan Weiner, MS, RDN, CDCES, FADCES, talks with Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM, about situations in which an ultra-long-acting insulin may be a good choice. Katelyn O’Brien ...

(RTTNews) - Danish pharmaceutical company Novo Nordisk A/S is recalling 1,468 product samples of Levemir, Tresiba, Fiasp, Novolog and Xultophy to the consumer level, due to improper storage ...

Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.

Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk will phase out, then permanently discontinue Levemir in the U.S. on December 31, 2024," the company said in a statement.